Celebrex In The News

Orange County Celebrex Drug Attorneys

At Bisnar | Chase, our California Celebrex attorneys and personal injury lawyers have been protecting the legal rights of seriously injured clients since 1978. If you have suffered as a result of taking the non-steroidal anti-inflammatory drug Celebrex, you may be at risk for serious and possibly deadly health problems. Our dangerous drug injury attorneys are respected by our clients and colleagues for our dedication to protecting our clients’ legal rights and the impressive amount of monetary compensation that we have recovered on behalf of our injured clients. If you or a loved one has suffered as the result of the prescription drug Celebrex, contact Bisnar | Chase today for a free consultation.

WARNING: If you are currently taking the prescription drug Celebrex, you may be at risk for serious health problems including heart attack and stroke.

FDA Public Health Advisory - Non-Steroidal Anti-Inflammatory Drug Products (NSAIDS)

FDA/Center for Drug Evaluation and Research - December 23, 2004

The FDA is issuing a public health advisory concerning use of non-steroidal anti-inflammatory drug products (NSAIDS) including those known as COX-2 selective agents.

Recently released data from controlled clinical trials showing that the COX-2 selective agents (Vioxx, Celebrex, and Bextra) may be associated with an increased risk of serious cardiovascular events (heart attack and stroke) especially when they are used for long periods of time or in very high risk settings (immediately after heart surgery).

Click here to read the entire story.

FDA Issues Public Health Advisory Recommending Limited Use of Cox-2 Inhibitors - Agency Requires Evaluation of Prevention Studies Involving Cox-2 Selective Agents

FDA Talk Paper - December 23, 2004

The Food and Drug Administration (FDA) today issued a Public Health Advisory summarizing the agency's recent recommendations concerning the use of non-steroidal anti-inflammatory drug products (NSAIDs), including those known as COX-2 selective agents. The public health advisory is an interim measure, pending further review of data that continue to be collected.

In addition, FDA today announced that it is requiring evaluation of all prevention studies that involve the Cox-2 selective agents Celebrex (celecoxib) and Bextra (valdecoxib) to ensure that adequate precautions are implemented in the studies and that local Institutional Review Boards reevaluate them in light of the new evidence that these drugs may increase the risk of heart attack and stroke. A prevention trial is one in which healthy people are given medicine to prevent a disease or condition (such as colon polyps or Alzheimer's disease).

Click here to read the entire story.

FDA Statement on the Halting of a Clinical Trial of the Cox-2 Inhibitor Celebrex

FDA Statement - December 17, 2004

The FDA today released the following statement on the halting of a clinical trial of the Cox-2 inhibitor Celebrex (celecoxib):

The Food and Drug Administration (FDA) learned last night from the National Cancer Institute (NCI) and Pfizer, Inc., that NCI has stopped drug administration in an ongoing clinical trial investigating a new use of Celebrex (celecoxib) to prevent colon polyps because of an increased risk of cardiovascular (CV) events in patients taking Celebrex versus those taking a placebo.

Click here to read the entire story.

Pfizer Defends Celebrex Vs. Deaths Report

By Associated Press November 4, 2004

NEW YORK -- Pfizer Inc. defended the safety of its painkiller Celebrex on Thursday after a newspaper reported that documents from Canadian health authorities linked the drug to the deaths of 14 people who were taking it over the past five years.

The documents include more than 100 adverse-reaction reports on Celebrex over the past five years, including 19 cases of heart attack, cardiac arrest or heart failure and five strokes, the Canadian newspaper National Post reported.

Click here to read the entire story.

Reports raise question of painkiller's safety

Associated Press November 4, 2004

TORONTO - Canadian health officials said Thursday they have received reports linking Pfizer painkiller Celebrex to 14 deaths and numerous heart-related side effects, but that it would be premature to issue a warning or pull it from the shelves.

Click here to read the entire story.

Vioxx recall raises prescribing questions

There are many other treatment options for people with arthritis, and physicians are considering them patient by patient.

By Susan J. Landers AMNews staff October 25, 2004

Washington -- Physicians are pulling out their risk-versus-benefit calculators once more to determine which patients, if any, should be switched to another COX-2 inhibitor in light of the fate of the popular drug Vioxx (rofecoxib), which was pulled from the market abruptly Sept. 30.

Click here to read the entire story.

Pfizer to Sponsor Major New Celebrex Clinical Trial

As Part of an Ongoing Research Program, Study Will Evaluate Potential Cardiovascular Benefits

NEW YORK, October 18, 2004 -- Pfizer Inc announced today it is sponsoring a major clinical study to further assess its COX-2 medication CELEBREX® (celecoxib) in osteoarthritis (OA) patients at high risk for cardiovascular disease.

Click here to read the entire story.

Other drugs might raise heart attack risk

Studies: Substance that prevents heart problems blocked

The Associated Press October 6, 2004

(AP) -- The arthritis drug Vioxx may not be the only drug of its type that raises the risk of heart attack and stroke, scientists suggest in a report released Wednesday by the New England Journal of Medicine.

That's contrary to what federal regulators said when the blockbuster pain reliever was pulled from the market last week.

Click here to read the entire story.

Do Two Popular Arthritis Drugs Increase Heart Attack Risk?

By Peggy Peck Web MD News August 21, 2001

Aug. 21, 2001 -- Heart researchers from the Cleveland Clinic Foundation say that the popular arthritis drugs Vioxx and Celebrex may increase the risk for heart attacks and are cautioning doctors to use the drugs very carefully, especially in people with heart disease.

Click here to read the entire story.